Drug Profile
Research programme: GABAA receptor modulators - Euthymics
Latest Information Update: 07 Sep 2010
Price :
$50
*
At a glance
- Originator DOV Pharmaceutical
- Developer Euthymics Bioscience
- Class
- Mechanism of Action GABA A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Anxiety disorders; Epilepsy; Insomnia
Most Recent Events
- 22 Jul 2010 Euthymics Bioscience acquires DOV Pharmaceutical
- 16 Nov 2007 Preclinical trials in Epilepsy in USA (unspecified route)
- 16 Nov 2007 Preclinical trials in Insomnia in USA (unspecified route)